Precision for Medicine与SOPHiA GENETICS合作，通过SOPHiA DDM™平台及其液体活检功能扩展生物制药服务-动脉网

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

CISION 等信源发布 2025-04-08 14:00



可切换为仅中文







The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster.

该合作整合了先进的AI驱动分析和临床试验解决方案，助力生物制药公司加速药物研发并更快地提供靶向治疗。

BETHESDA, Md.

贝塞斯达，马里兰州

and

和

BOSTON

波士顿

and ROLLE,

和罗尔，

Switzerland

瑞士

，

April 8, 2025

2025年4月8日

/PRNewswire/ --

Precision for Medicine,

精准医疗，

a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and precision medicine services. As part of this collaboration, Precision for Medicine will integrate the SOPHiA DDM™ Platform for biomarker discovery, clinical trial assays (CTAs), and advanced algorithms to expand clinical trial capabilities.

一家领先的药物开发和商业化服务提供商，今天宣布与SOPHiA GENETICS达成战略合作伙伴关系，以加强其生物标志物发现和精准医疗服务。作为合作的一部分，Precision for Medicine将整合SOPHiA DDM™ 平台用于生物标志物发现、临床试验检测（CTAs）和先进算法，以扩展临床试验能力。

This partnership will further enhance service offerings and provide biopharma companies with tools to accelerate clinical trial design, patient stratification, and data analysis..

该合作将进一步提升服务范围，为生物制药公司提供加速临床试验设计、患者分层和数据分析的工具。

Through this partnership, Precision for Medicine will leverage the SOPHiA DDM

通过该合作，Precision for Medicine 将利用 SOPHiA DDM

商标

Platform's advanced AI-driven algorithms to analyze complex multimodal data, including genomic, radiomic, and clinical data. This capability will allow biopharma companies to identify and target the most appropriate patient populations for clinical trials, accelerating biomarker discovery and improve diagnostic capabilities.

平台利用先进的AI驱动算法来分析复杂的多模态数据，包括基因组、放射组和临床数据。这一能力将使生物制药公司能够识别并锁定最适合临床试验的患者群体，加速生物标志物的发现并提升诊断能力。

This is crucial for precision medicine efforts in oncology, rare diseases, and genetic disorders, where understanding the specific genomic characteristics of each patient may enable more targeted therapies..

这在肿瘤学、罕见病和遗传疾病方面的精准医疗工作中至关重要，因为了解每位患者的特定基因组特征可能有助于实现更有针对性的治疗。

Additionally, MSK-ACCESS

此外，MSK-ACCESS

powered with SOPHiA DDM

由SOPHiA DDM提供支持

商标

, an innovative liquid biopsy test being deployed globally with the support of AstraZeneca, will be made available as a Precision for Medicine service for biopharma clients. Data generated by this genomically rich, globally deployed test will enable retrospective clinical trial data analysis and improve patient stratification.

，一种在全球范围内推出、并得到阿斯利康支持的创新液体活检测试，将作为精准医学服务提供给生物制药客户。这项基因信息丰富、全球部署的测试所生成的数据，将能够实现回顾性临床试验数据分析，并改进患者分层。

This capability allows biopharma companies to refine and optimize their clinical trial designs by better understanding how patients responded to previous treatments. This evidence-based approach can help companies fine-tune their drug development strategies, improve patient recruitment for trials, and gain deeper insights into the efficacy of therapies in real-world settings..

这种能力使生物制药公司能够通过更好地了解患者对以往治疗的反应来改进和优化其临床试验设计。这种基于证据的方法可以帮助公司微调药物开发策略、改善试验患者的招募，并在真实世界环境中更深入地了解疗法的有效性。

'We're thrilled to partner with SOPHiA GENETICS to integrate the SOPHiA DDM

“我们很高兴与SOPHiA GENETICS合作，将SOPHiA DDM整合进来

商标

Platform and integrate MSK-ACCESS

平台并整合MSK-ACCESS

powered with SOPHiA DDM

由SOPHiA DDM驱动

商标

into our offering, providing biopharma companies with the tools to accurately identify the right patient populations for enrollment into clinical trials,' said

引入我们的产品中，为生物制药公司提供工具，以准确识别适合纳入临床试验的正确患者群体，”

Darren Davis

达伦·戴维斯

, PhD, Senior Vice President Precision for Medicine. 'By leveraging AI-powered algorithms and machine learning, we can pinpoint biomarkers and genomic signatures that enable more efficient, targeted trials and improve therapeutic efficacy. This ultimately helps speed up patient enrollment, reduce trial costs, and bring therapies to market faster.'.

博士，精准医学高级副总裁。 “通过利用人工智能算法和机器学习，我们可以精确定位生物标志物和基因组特征，从而实现更高效、更有针对性的试验，并提高治疗效果。这最终有助于加快患者招募，降低试验成本，并更快地将疗法推向市场。”

Through this partnership, Precision for Medicine will provide wet lab services, alongside data analysis and clinical trial support, offering biopharma companies expanded capabilities under one umbrella. This integrated approach allows clients to rely on a single solution provider, with Precision for Medicine and SOPHiA GENETICS working together to deliver seamless end-to-end support for their drug development programs..

通过这一合作，Precision for Medicine将提供湿实验室服务、数据分析和临床试验支持，为生物制药公司提供一站式扩展能力。这种整合方式使客户能够依赖单一解决方案提供商，Precision for Medicine与SOPHiA GENETICS携手合作，为其药物开发项目提供无缝的端到端支持。

'Our collaboration with Precision for Medicine enables us to expand the reach and impact of our SOPHiA DDM

“我们与Precision for Medicine的合作使我们能够扩大SOPHiA DDM的覆盖范围和影响力

商标

Platform and deliver real-time actionable insights across the clinical trial continuum,' said

平台并提供整个临床试验过程中的实时可行洞察，'

Ross Muken

罗斯·穆肯

, President at SOPHiA GENETICS. 'By combining our AI-powered Platform with Precision for Medicine's cutting-edge clinical trial solutions, we can deliver comprehensive, data-driven capabilities to biopharma companies, accelerating the path to market for precision therapies.'

索菲亚遗传学公司的总裁表示：“通过将我们的人工智能平台与Precision for Medicine领先的临床试验解决方案相结合，我们可以为生物制药公司提供全面的、数据驱动的能力，加速精准治疗进入市场的进程。”

Precision for Medicine's established clinical trial expertise, including biomarker testing and wet lab services, combined with SOPHiA GENETICS' AI-based genomic analysis tools, creates a powerful comprehensive solution for biopharma companies. Biopharma clients can now accelerate drug development with a seamless solution for data analysis and clinical support, enabling more efficient progression from preclinical research to market readiness.

Precision for Medicine成熟的临床试验专业知识，包括生物标志物检测和湿实验室服务，结合SOPHiA GENETICS基于人工智能的基因组分析工具，为生物制药公司提供了一个强有力的综合解决方案。生物制药客户现在可以通过一个无缝的数据分析和临床支持解决方案来加速药物开发，从而更高效地从临床前研究推进到市场准备阶段。

This collaboration provides a competitive edge, allowing clients to bring innovative therapies to patients faster and improve market positioning in the highly competitive biopharma landscape..

这种合作提供了竞争优势，使客户能够更快地将创新疗法带给患者，并在竞争激烈的生物制药领域中改善市场定位。

This exciting partnership is a key driver of innovation in precision medicine, providing biopharma companies with tools to better understand patient genomic makeup and develop personalized treatments for complex diseases. The collaboration enables biopharma companies to tailor treatments based on specific genomic profiles, with the potential to enhance outcomes, patient satisfaction, and the market value of their products.

这一令人兴奋的合作伙伴关系是推动精准医学创新的关键因素，为生物制药公司提供工具，以更好地了解患者的基因组构成，并为复杂疾病开发个性化治疗方案。该合作使生物制药公司能够根据特定的基因组图谱定制治疗方案，有望改善治疗效果、提高患者满意度并增加其产品的市场价值。

This patient-centric approach aims to fuel breakthroughs in oncology, rare diseases, and other high-unmet-medical areas..

这种以患者为中心的方法旨在推动肿瘤学、罕见病和其他高未满足医疗需求领域的突破。

About Precision for Medicine

关于Precision for Medicine

Precision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise and advanced data intelligence.

Precision for Medicine 是首家以生物标志物驱动的临床研究与开发服务组织，支持生命科学公司使用对更精准有效针对患者治疗至关重要的生物标志物。Precision 采用一种变革性的临床研究方法，将临床试验设计与执行、深厚的科学知识、实验室专长以及先进的数据智能相结合。

This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,400 people in 40 locations globally across .

这种融合正在推动更快的临床开发和审批。Precision for Medicine是Precision Medicine Group的一部分，该集团在全球40个地点拥有3400名员工。

North America

北美

，

Europe

欧洲

and

和

Asia-Pacific

亚太地区

. For more information, visit PrecisionForMedicine.com.

有关更多信息，请访问 PrecisionForMedicine.com。

Contact

联系

Brad Epstein

布拉德·爱泼斯坦

Brad.epstein@precisionformedicine.com

布拉德·爱泼斯坦@精准医学.com

About SOPHiA GENETICS

关于SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq:

SOPHiA GENETICS（纳斯达克：

SOPH

标准操作程序

) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn..

是一家云原生医疗技术公司，致力于通过使用人工智能解锁数据洞察，推动数据驱动医学的普及，为全球患者提供世界级的医疗服务。该公司是SOPHiA DDM™平台的创建者，该平台能够分析复杂的基因组和多模态数据，并为全球范围内的医院、实验室和生物制药机构网络提供实时、可操作的洞察。欲了解更多信息，请访问SOPHiAGENETICS.COM，并在LinkedIn上与我们联系。

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.

SOPHiA GENETICS产品仅供研究使用，不得用于诊断程序，除非另有说明。本新闻稿中的信息涉及可能在不同国家可用或不可用的产品，并且如果适用的话，这些产品可能已经或者尚未获得政府监管机构对于不同用途的批准或许可。

Please contact .

请联系。

support@sophiagenetics.com

to obtain the appropriate product information for your country of residence.

获取适合您居住国的产品信息。

SOPHiA GENETICS Forward-Looking Statements:

SOPHiA GENETICS 前瞻性声明：

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements.

本新闻稿包含构成前瞻性陈述的声明。本新闻稿中除历史事实陈述外的所有声明，包括关于我们未来经营结果和财务状况、业务战略、产品和技术的声明，以及管理层对未来运营的计划和目标，均为前瞻性陈述。

Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S.

前瞻性声明基于我们管理层的信念和假设，以及目前可供我们管理层使用的信息。这些声明受风险和不确定性的影响，由于各种因素，包括我们在美国提交的文件中描述的因素，实际结果可能与前瞻性声明中明示或暗示的结果有重大差异。

Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law.

证券交易委员会。无法保证一定能实现这样的未来结果。本新闻稿中包含的此类前瞻性陈述仅代表截至本日期的情况。我们明确声明，不承担任何更新本新闻稿中包含的这些前瞻性陈述的义务或承诺，以反映我们预期的任何变化或事件、条件或情况的任何变化，除非适用法律要求。

No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements..

对于任何此类前瞻性陈述的准确性，不作任何（明示或暗示）的声明或保证。

Media Contact:

媒体联系人：

Kelly Katapodis

凯莉·卡塔波迪斯

media@sophiagenetics.com

Logo -

标志 -

https://mma.prnewswire.com/media/2659731/Precision_For_Medicine_Logo.jpg

WANT YOUR COMPANY'S NEWS